Results for tag: "Aptiom"

Aptiom is a central nervous system (CNS) drug used to treat seizures associated with epilepsy. It is an antiepileptic drug (AED) that works by decreasing the abnormal electrical activity in the brain. Aptiom is available in both immediate-release and extended-release formulations, allowing for more flexibility in dosing. It is also available in combination with other AEDs, allowing for more tailored treatment. Aptiom is generally well-tolerated, with the most common side effects being dizziness, drowsiness, and headache. The Aptiom market is composed of a variety of companies, including Sunovion Pharmaceuticals, Eisai Co., Ltd., and UCB Pharma. Sunovion Pharmaceuticals is a global biopharmaceutical company that develops and markets Aptiom and other CNS drugs. Eisai Co., Ltd. is a Japanese pharmaceutical company that specializes in CNS drugs, including Aptiom. UCB Pharma is a biopharmaceutical company that develops and markets Aptiom and other CNS drugs. Show Less Read more